Halozyme Therapeutics Inc

HALO · Moat type: REGULIERUNG

MoatScore

7/10

Fair Value

69 USD

Margin of Safety

-10.9 %

Rating

BEOBACHTEN

GESCHÄFTSMODELL Halozyme Therapeutics licenses its patented ENHANZE technology (enzymatic drug delivery subcutaneously) to pharmaceutical companies that use it to develop subcutaneous formulations of their medications, and collects licensing fees and milestone payments – without having to bear costly clinical trials itself.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.